---
title: "Bristol Myers Squibb Announces Dividend Increase | BMY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/269285903.md"
description: "Bristol Myers Squibb announced a quarterly dividend increase to $0.63 per share, marking a 1.6% rise from last year's rate. The annual dividend rate for 2026 is set at $2.52 per share. This is the 17th consecutive year of dividend increases and the 94th year of dividend payments. Additionally, a $0.50 dividend per share on convertible preferred stock was declared. The dividends are payable in February and March 2026."
datetime: "2025-12-10T13:16:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269285903.md)
  - [en](https://longbridge.com/en/news/269285903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269285903.md)
---

# Bristol Myers Squibb Announces Dividend Increase | BMY Stock News

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on February 2, 2026, to stockholders of record at the close of business on January 2, 2026.

This quarterly dividend represents a 1.6% increase over last year’s quarterly rate of sixty-two cents ($0.62) per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2026 is $2.52 per share. This marks the 17th consecutive year that the company has increased its dividend and the 94th consecutive year that the company has paid a dividend.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 2, 2026, to stockholders of record at the close of business on February 3, 2026.

**About Bristol Myers Squibb: Transforming Patients’ Lives Through Science**

At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20251210079955/en/

**Media Relations:**  
media@bms.com

**Investor Relations:**  
investor.relations@bms.com

Source: Bristol Myers Squibb

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Trump's lawsuit against Wall Street Journal over Epstein story dismissed for now](https://longbridge.com/en/news/282552899.md)
- [Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans | BMS Stock News](https://longbridge.com/en/news/270348686.md)
- [Chemtrade Logistics Income Fund Declares April 2026 Distribution | CGIFF Stock News](https://longbridge.com/en/news/283508611.md)
- [Southern Company increases dividend for 25th consecutive year | SO Stock News](https://longbridge.com/en/news/283389531.md)
- [Peyto Exploration & Development declares CAD 0.11 dividend](https://longbridge.com/en/news/283010250.md)